On November 9, WUXI BIO rose 3.4% in Regular Trading, trading at HK$49.48, with turnover of HK$244 million.
The move was supported by continued market focus on the company’s previously announced exclusive development agreement with Fresenius and expectations for a possible guidance upgrade after it was placed on a 90-day upside catalyst watchlist.
Background context shows Fresenius secured exclusive options over up to 37 identified biosimilar candidates over the next 10 years, in what has been described as the largest development agreement announced so far in the biosimilars industry. The candidates correspond to originator drugs with aggregate annual list-price sales of more than EUR370 billion. In parallel, recent analyst commentary indicated WUXI BIO could raise overall guidance in the fourth quarter, while another major broker maintained a Buy rating and a HK$62 target price, reinforcing sentiment around order visibility and medium-term growth.
The company provides end-to-end solutions for biologics discovery, development and manufacturing, and also operates an ADC-focused CRDMO business through WuXi XDC.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments